News from cardio3 biosciences A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( Tokyo:4568,OTC-PINK:DSNKY)

Dec 19, 2014, 10:03 ET

Cardio3 Biosciences Announces the Enrolment of the 240th Patient for its CHART-1 Phase III Clinical Trial for the Treatment of Heart Failure

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Dec 17, 2014, 03:00 ET

Cardio3 Biosciences Will be Present at ODDO Midcap Forum

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation...

Dec 15, 2014, 09:00 ET

Cardio3 Biosciences to Address American Institutional Investors in January at J.P. Morgan Healthcare Conference

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the development of regenerative therapies, announces its participation...

Nov 26, 2014, 04:00 ET

Cardio3 BioSciences Announces the Nomination of Three Co-principal Investigators for its CHART-2 Phase III Clinical Trial of C-Cure® for the Treatment of Heart Failure

- Dr Bernard J. Gersh, Dr Thomas Povsic and Dr Gerasimos Filippatos will be Co-Principal Investigators of the phase III clinical trial...

Nov 18, 2014, 11:45 ET

Cardio3 BioSciences Announces Q3 2014 Business Update

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Nov 05, 2014, 12:01 ET

Cardio3 BioSciences Acquires CorQuest Medical Inc.

  - Cardio3 BioSciences acquires CorQuest Medical Inc. and its unique heart access platform that could receive CE marking by end...

Oct 23, 2014, 02:00 ET

Cardio3 Biosciences Appoints Dr. Warren Sherman as Chief Medical Officer

Cardio3 BioSciences (C3BS) (Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Oct 13, 2014, 11:45 ET

Cardio3 Biosciences Receives Authorization to Enroll Patients in Switzerland in its Phase III Clinical Trial Chart-1

- CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart...

Oct 08, 2014, 01:00 ET

Cardio3 BioSciences Awarded Preferred Access Rights to Mayo Clinic Center for Regenerative Medicine Portfolio

- Agreement broadens long-standing research and development collaboration and ensures Cardio3 BioSciences' preferred access to Mayo Clinic...

Oct 01, 2014, 02:24 ET

Cardio3 Biosciences Announces New Business Development Strategy To Broaden Its Product Pipeline

- Cardio3 BioSciences' business development strategy will be articulated around a technology pillar - cellular therapies - and a clinical...

Feb 24, 2014, 08:24 ET

Cardio3 BioSciences Strengthens IP Portfolio with New US Patent

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Jan 09, 2014, 09:00 ET

Cardio3 BioSciences Receives IND Clearance from the FDA for its CHART-2 Phase III Heart Failure Clinical Trial

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Dec 30, 2013, 06:30 ET

Cardio3 BioSciences Announces Participation at the 32nd Annual JP Morgan Healthcare Conference in San Francisco

Cardio3 BioSciences (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Dec 16, 2013, 13:27 ET

Cardio3 BioSciences Raises € 4.0 Million in Non-dilutive Funding from the Walloon Region

The biotechnology company, Cardio3 BioSciences SA ('Cardio3' or 'the Company'), a leader in the discovery and development of regenerative,...

Dec 11, 2013, 12:00 ET

Cardio3 BioSciences C-Cath® Article Published in Circulation Cardiovascular Interventions

  Study Demonstrates Enhanced Endomyocardial Therapeutics Retention through an Optimized Delivery System Cardio3 BioSciences (C3BS) (NYSE...

Dec 03, 2013, 11:35 ET

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 6.8 Million FP7 Research Grant for AMCARE Program

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Nov 25, 2013, 05:49 ET

Cardio3 BioSciences Partner and Exploitation Manager of a Eur 4.5 Million FP7 Research Grant

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Nov 21, 2013, 03:00 ET

Cardio3 BioSciences Wins Trends-Tendances Business Tour Most Innovative Company Award 2013 for Wallonia

The Belgian biotechnology company Cardio3 BioSciences (C3BS)(NYSE Euronext Brussels and Paris : CARD), leader in the discovery and...

Nov 12, 2013, 12:26 ET

Cardio3 BioSciences Announces Q3 2013 Business Update and Authorization to Enroll Patients in Poland in its Chart-1 Phase III Clinical Trial

Cardio3 BioSciences SA (C3BS) (NYSE Euronext Brussels and Paris: CARD), a leader in the discovery and development of regenerative, protective and...

Oct 23, 2013, 05:56 ET

Cardio3 BioSciences Receives Authorization to Enroll Patients in Italy in its Phase III Clinical Trial CHART-1

- CHART-1 trial represents the world's first Phase III trial in regenerative medicine for a pre-programmed cellular therapy targeting heart...